{"id":"NCT02576717","sponsor":"Celgene","briefTitle":"A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis","officialTitle":"A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-16","primaryCompletion":"2023-01-05","completion":"2023-01-05","firstPosted":"2015-10-15","resultsPosted":"2024-01-30","lastUpdate":"2024-01-30"},"enrollment":2494,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"RPC1063","otherNames":["Ozanimod"]}],"arms":[{"label":"1 mg RPC1063 (Ozanimod) oral capsule","type":"EXPERIMENTAL"}],"summary":"The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.","primaryOutcome":{"measure":"Number of Participants Experiencing Adverse Events (AEs)","timeFrame":"From first dose to 90-days post last dose (an average of 65 months up to a max of 85 months)","effectByArm":[{"arm":"Parent Treatment Group IFN-B-1a 30 ug","deltaMin":668,"sd":null},{"arm":"Parent Treatment Group: RPC1063 0.5 mg","deltaMin":775,"sd":null},{"arm":"Parent Treatment Group: RPC1063 1.0 mg","deltaMin":776,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":175,"countries":["United States","Belarus","Belgium","Bosnia and Herzegovina","Bulgaria","Croatia","Estonia","Georgia","Germany","Greece","Hungary","Italy","Latvia","Lithuania","Moldova","New Zealand","Poland","Portugal","Romania","Serbia","Slovakia","South Africa","Spain","Sweden","Ukraine","United Kingdom"]},"refs":{"pmids":["40698614","39018016","38130041","37550942"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":37},"commonTop":["Nasopharyngitis","Headache","COVID-19","Upper respiratory tract infection","Lymphopenia"]}}